Henry Ford Health

Henry Ford Health Scholarly Commons
Nephrology Articles

Nephrology

7-1-2011

Albuminuria and Prognosis in CKD: Truth Be Told
Jerry Yee
Henry Ford Health, JYEE1@hfhs.org

Follow this and additional works at: https://scholarlycommons.henryford.com/nephrology_articles

Recommended Citation
Yee J. Albuminuria and Prognosis in CKD: Truth Be Told. Advances in Chronic Kidney Disease 2011;
18(4):219-221.

This Article is brought to you for free and open access by the Nephrology at Henry Ford Health Scholarly
Commons. It has been accepted for inclusion in Nephrology Articles by an authorized administrator of Henry Ford
Health Scholarly Commons.

Ackd
Advances in Chronic Kidney Disease

Vol 18, No 4, July 2011

EDITORIAL

Albuminuria and Prognosis in CKD: Truth Be Told

I

n this issue of Advances in Chronic Kidney Disease, Guest
Editors de Zeeuw, Parekh, and Soman have composed
a synthesis of the known knowns and known unknowns
regarding proteinuria. Correspondingly, the authors reveal the truth, as they know it, regarding a host of proteinuric entities, which will be considered problems of
albuminuria for the purposes of this discussion.
In 1750, Cotugno first coined the term albuminuria
from a patient with nephrosis and ‘‘dropsy.’’ Despite that
he erred in his conception of why the urine of his patient
contained albumin, nonetheless, he associated albuminuria with a disease state.1 He and others, including
Richard Bright, were clearly cognizant of the prognostic
importance of heavy albuminuria in nephrotic syndromes, even then. Their observations were subsequently
documented and have been repeatedly confirmed at
patient- and trial-levels. In recognition of the clinical importance of proteinuria, the National Kidney Foundation
proposed an albuminuria screening strategy that would
limit false-positive results and amplify the sensitivity of
testing. The albuminuria algorithm called for 2 additional,
separate examinations over 3 to 6 months, to unequivocally establish albuminuria.2 However, the additional testing for higher grade albuminuria may be unnecessary
because higher levels of albuminuria persisted in all
instances, at a median follow-up interval of 17 days.3
Albuminuria is important and is accepted in some circles as a CKD biomarker. However, it is not a surrogate
endpoint for CKD because it fails to adequately fulfill
the Prentice criteria: (i) A valid surrogate endpoint must
be statistically correlated with the true clinical endpoint
and should predict the clinical outcome of interest.
(ii) A valid surrogate endpoint must fully capture the
treatment’s aggregate effect on the true clinical endpoint
and should account for every major effect of the treatment.4 In accordance with these tenets, a Pro and Con
debate, ‘‘Microalbuminuria heralds a poor prognosis,’’
was staged at the National Kidney Foundation’s Spring
Clinical Meetings in 2011. Before either speaker presented his case, the participants demonstrated their

enthusiasm for the hypothesis, and nearly three-fourths
of those present voted affirmatively. At the end of the session, there was a 10% dropoff. The majority had prevailed, but was it correct?
Following glomerular ultrafiltration, the concentration
of albumin in Bowman’s space is approximated at just 4
mg/L. Consequently, the importance of albumin’s appearance in the final urine might seem disproportionately large.
Indeed, albumin represents a minority of urinary protein in
the normal individuals. It had long been held that normal
individuals would not excrete albumin in an amount
.0.5 to 1 g/d, in the total absence of proximal tubular
albumin reabsorption. This concept has been recently challenged, and some contend that nephrotic range proteinuria
from physiologic glomerular sieving of albumin may be the
norm.5 Albumin’s complex traversal through the tripartite
barriers of endothelium, glomerular basement membrane,
and podocytes is considered a failure of glomerular permselectivity, and success is represented by retardation of
albumin’s passage into the ultrafiltrate. Glomerular impediment to passage of protein is influenced not only by structural pathobiology but also by extraglomerular factors.
Inflammation accompanied by elevated cytokine levels
may lead to proteinuria as may heightened intraglomerular
capillary pressure, hyperglycemia, severe acute kidney injury, sepsis, exercise, fever, heart failure, and other states of
sympathetic nervous system hyperactivation that are frequently accompanied by elevated angiotensin II levels. In
the end, it is albumin that escapes proximal tubular reclamation with transcytosis to the basolateral membrane
that ultimately determines albuminuria. Thus, persistent
albuminuria (fixed proteinuria) represents its collective escape from damaged glomeruli and tubuli.
The process of measurement and quantitation usually
occurs first by albumin’s association with a cationic

Ó 2011 by the National Kidney Foundation, Inc. All rights reserved.
1548-5595/$36.00
doi:10.1053/j.ackd.2011.06.007

Advances in Chronic Kidney Disease, Vol 18, No 4 (July), 2011: pp 219-221
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on June 22, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

219

220

Yee

dye-impregnated urine dipstick, and later by either
a urine protein-to-creatinine ratio (PCR) or albumin-tocreatinine ratio (ACR). However, there is a significant
correlation between the semiqualitative dipstick and
more quantitative protein concentration testing,6 which
is not widely appreciated. Historically, the PCR preceded
the standardization and automation of ACR by many
years, and was the parameter upon which many triallevel data are based. The ACR is conducted with standardized technology and antibodies specifically directed
against albumin, whereas the PCR may be carried out
with various pH indicator dyes.7 Consequently, the
ACR is considered the method of choice by standardsand guidelines-producing bodies and organizations.
Remarkably, fragmented albumin, a byproduct of tubular
processing, may not be detected by ‘‘gold standard’’
albumin-specific antibodies because these were generated against intact molecules. In addition, the variability
of urine albumin excretion may exceed the coefficient of
variation of the test itself, thereby making trend analysis
less precise. To reduce the variability, there is an advantage to performing morning ACRs.8
Ironically, the indicator dye-based protein concentration
measurements will quantitate these ‘‘missed’’ fragments,
the residua of tubular albumin metabolism. For this reason
some have advocated that PCR evaluations are superior
to ACRs for detection of albuminuria. Moreover, PCRs detect other, nonalbumin proteins, including those of lower
(eg, b2 microglobulin, light chains) and higher (eg, intact
immunoglobulins) molecular weight. However, PCRs
cannot discriminate among the various urinary proteins.
Therefore, the ACR is clearly superior to the PCR, even in
some tubular disorders.9 Exceptions occur in circumstances in which a nonalbumin protein constitutes the principal urinary protein rather than albumin. The clinical
scenarios in which this issue becomes paramount are few
(eg, myeloma, Dent’s disease), and the associated systemic
disorders are typified by paraproteins that incite substantial glomerular and/or tubular pathology.
Microalbuminuria, at any given time, only indicates that
there is deviation from normality in glomerulotubular processing. Neither the mechanism(s) nor the site(s) of disrupted physiology and their respective magnitudes may be
elucidated clinically. Furthermore, the durations of past
or future protein excretion cannot be prognosticated either.
Trend analysis extending over months to years may be required to determine progression of CKD and the accrual
of risk, particularly cardiovascular risk. To this end, a Kidney Disease: Improving Global Outcomes (KDIGO) CKD
Prognosis Consortium qualitated risk by melding the estimated glomerular filtration rate with the degree of albuminuria.10 To determine the joint contribution to ESRD
and other renal outcomes, the Consortium conducted
a meta-analysis of 9 general population cohorts (N ¼ 845,
125 participants) plus 8 additional cohorts (N ¼ 173, 892
patients) with high risk for CKD. Their meta-analysis

confirmed that lower estimated glomerular filtration rate
plus albuminuria, quantitated as a single ACR measurement, imposed greater risk for cardiovascular and kidney
disease outcomes than either alone.
More recent data from a retrospective analysis of 10,
290 diabetic, hypertensive patients from a Kaiser Permanente population-based sample characterized the course
of these hypertensive and diabetic individuals.11 Of 3187
patients with microalbuminuria, 668 regressed to normoalbuminuria, 630 progressed to macroalbuminuria,
and of these, just 10 developed ESRD. Of the 5908
persons who were originally normoalbuminuric, 2839
developed microalbuminuria, of which 370 developed
macroalbuminuria. Five of the last group developed
ESRD. Of the 1195 originally macroalbuminuric subjects,
52 progressed to ESRD, with likely tubulointerstitial
fibrosis invoked by a proteinuria-induced, cytokinemediated inflammation. These data underscore both
sides of the original tenet. Essentially, microalbuminuric
risk for progression to ESRD varied as a function of the
degree of extant diabetic kidney disease at the time of entry into the study and was subsequently altered by
physician-driven therapy. Clearly, within each stratum,
some patients may have responded less well than the
group as a whole and progressed to ESRD. Again, this
must be taken within the context of trend analysis. The
latter allows for treatment effects that mitigate microalbuminuria, which may also include therapies extrinsic
to the kidneys, such as those for heart failure. Essentially,
if albuminuria is worsening, risk factor management
should commensurately increase, not only for albuminuria but also for other parameters, such as glycemic control, elevated blood pressure, and dyslipidemia.2
The overall literature reflects the same verisimilitudes:
treatment responders have better prognoses than nonresponders. Unlike the Pisse Prophets who simply divined
the urine, nephrologists must conduct trend analysis;
they must define, measure, and measure again urinary
albumin from those with CKD so as to extrapolate its prognostic import.12 This truth has been known for a long time
and reminds of us the following words of physicianphilosopher, William James, in his work, Pragmatism:
‘‘When a thing is new, people say ‘It is not true.’ Later,
when its truth becomes obvious, they say ‘It is not important.’ Finally, when its importance cannot be denied, they
say ‘Anyway, it is not new.’’’ And equally important,
‘‘Beliefs are considered to be true if and only if they are
useful and can be practically applied.’’13
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